Immune system is crucial for the development and progression of immune-mediated and non-9
We used the NMF package 25 in R and applied the non-negative matrix factorization method 1 3 1 using Brunet's 26 algorithm to the expression matrix (X D ) to factor it into two matrices namely 1 3 2 W D and H D such that. where, k is the number of classes/clusters that splits the data, such that it satisfies the above The NMF algorithm clusters the data into k clusters such that, in each cluster 'i', where i 1 4 6
(1, …, k), the genes that have high values in ‫ݓ‬ are constitutively expressed by the cells that Identifying the key cluster 1 5 6
We then identified the largest weighted cluster among the k clusters identified by the NMF. That is, the subset of genes and cells of X D that can capture most of its expression pattern. We 1 5 8 did this by using the following approach. Since X D, W D and H D can be represented as below: 
The scores were scaled between 0 and 1, with 1 representing the cell or gene with the highest 1 7 3 score. To identify common mechanisms between two diseases, we looked at their overlapping cell-1 7 7 gene connections in their corresponding DIME networks. Jaccards' index (JI) was used to 1 7 8 measure the overlap between the two diseases with Fisher's exact test (FET) used to obtain 1 7 9 confidence p-value for the given overlap. The overlapping genes were used to calculate JI and 1 8 0 statistical significance of overlap using FET. The pleiotropy based overlapping cell-gene 1 8 1 network between the two diseases is referred to as the DIME-pleiotropy network. The drug to gene target database from DGIdb was downloaded 27 . The data was filtered to 1 8 5 contain only the CHEMBL interactions and only those pertaining to the drugs approved by 1 8 6 the food and drug administration (FDA) of USA. This FDA approved drug to gene target 1 8 7 interaction serves as the drug-gene network in this study. To identify potential drug 1 8 8 candidates from the drug-gene network for disease D, we choose its key DAG D as identified 1 8 9 in the previous step and extracted its corresponding target drugs from the drug-gene network. This network between the drugs and the key DAG D is referred to as the DIME-drug network 1 9 1 for disease D. The DIME-drug network represents all the drugs that target the key DAG D 1 9 2 identified in the given DIME network. To identify potential common acting drugs between 1 9 3 different diseases, we used their corresponding DIME-pleiotropy network and extracted the 1 9 4 drug-gene connections between the cell-gene and the drugs in drug-gene network. The drugs 1 9 5 identified using this approach represent those that act on the common mechanisms between 1 9 6 the two diseases and can be potential candidates for drug repurposing. The filtered disease-gene network of the DisGeNet comprised of DAGs for about 15,367 2 0 0 diseases. This could make the pleiotropy analysis between diseases extremely cumbersome, 2 0 1 with the number of disease-to-disease comparisons reaching as large as 118,064,661. Additionally, to have sufficient number of DAC-DAG associations in the DIME-pleiotropy 2 0 3 network and also have sufficient number of drug-target gene associations in the DIME-drug 2 0 4 network, we used a smaller subset of diseases but with larger DAGs associated to them. We with ≥ 100 DAGs were fewer in number, i.e., 613 diseases. This was sufficiently large DAC- presented in this study have been performed on this disease subset. To construct the DIME and DIME-drug network for other diseases not mentioned in this 2 1 3 study or using a custom gene input, we built a tool in R/Bioconductor called DIME that is 2 1 4 available as a shiny app (https://bitbucket.org/systemsimmunology/dime). The app can be 2 1 5 used to identify the key DAC, DAG and the DIME-drug network for the diseases from the 2 1 6
DisGeNet, the EBI-GWAS catalogue or for custom set of genes from the user. The aim of this study is to identify disease associated cell types (DACs) based on the existing 2 2 0 disease gene network, and to further identify disease associated gene (DAG) subsets that may 2 2 1 perturb the associated immune cells. To achieve this, we integrated our immunome data with 2 2 2 the disease network from DisGeNet and used the non-negative matrix factorization (NMF) 2 2 3 method to identify those subsets of genes and cells that maximally represent the Disease gene IMmune cell Expression (DIME) network, as illustrated in Figure 1A . The constructed 2 2 5 immunome dataset comprises 40 different cell types and is the largest bulk RNASeq meta-2 2 6 dataset of the immune cell types known to us. The filtered disease-gene network from 2 2 7 9 DisGeNet consists of associations between 15,367 diseases and 13,510 DAGs. In this 2 2 8 massive disease network, numerous DAGs were found to be common between both 2 2 9 phenotypically similar and distinct diseases. We explore these common DAG patterns in 2 3 0 more detail in the next section. Headings) terms ( Figure 1B) . The MeSH-MeSH network in Figure 1B MeSH term was the most well connected disease category in the network. The highest 2 3 8 number of common DAGs (6,959 DAGs) between two different MeSH terms was observed 2 3 9 between neoplasm and digestive system diseases. Other top MeSH-MeSH connections that 2 4 0 had more than 5,000 common DAGs include those between neoplasm and that of the skin and shared DAGs across phenotypically distinct diseases belonging to different MeSH terms.
4 4
We further studied the DAG patterns across MeSH terms and found that TP53 was MeSH terms such as immune system diseases, nervous system diseases, and skin and 2 4 8 connective tissue diseases. Similarly, TNF was associated with numerous diseases from 2 4 9 various MeSH terms including immune system diseases ( Figure 1D) . APOE was largely 2 5 0 associated with nervous system diseases, and ACE was largely associated with cardiovascular 2 5 1 diseases (Figure 1E and F) . TLR4 and CXCL8 were prevalently associated to several MeSH 2 5 2 terms (Figure 1G and H) . The above-mentioned genes (Figure 1C-1F ) are those that are 2 5 3 either the top represented (degree) genes across all diseases or for disease within specific mechanisms between phenotypically distinct diseases. These genes that are associated to 2 5 8 many diseases/MeSH terms (i.e. having high degree) were regarded as the hub genes of the DACs implicated in the disease. We then explored the DIME network of different kinds of rheumatic and/or fibrotic diseases, and their DACs (Figure 2B) . For systemic scleroderma, myeloid cells (neutrophils, CD4 + T regulatory, ILC3, and ILC2) were identified as key cluster of DACs (see methods). The key DAGs contributing to this cluster included PTPRC, FOS, SRRM2, MSN, JUNB, Figure 3A) . Of which, 3 2 4 evidently, TGF beta is known to play an essential role in the pathogenesis of fibrosis 33 .
2 5
Likewise, the neutrophil degranulation pathway or otherwise known as NETosis, is the 3 2 6 mechanism by which neutrophils exhibit defensive mechanisms to trap and kill foreign 3 2 7 bodies 34 . And this pathway has been found to be implicated in other autoimmune diseases, and is now being currently investigated in clinical trials 35 . Interestingly, we found neutrophils 3 2 9
and its NETosis associated genes to be in the top cluster of the DIME network for systemic
We then constructed the DIME network of another fibrotic disease, pulmonary fibrosis. The 3 3 2 DIME network revealed 4 DAC clusters for pulmonary fibrosis (Figure 2C) . Similar to in DAGs associated with TGF beta signaling (Supplementary Figure 3B) . Interestingly, we 3 3 5 also found that for pulmonary fibrosis neutrophils-granulocytes, macrophages, that of systemic scleroderma, (Supplementary Figure 3B) . We also found an enrichment of We then studied the DIME network of SLE, an autoimmune disease. The DIME network 3 4 1 revealed 2 DAC clusters for SLE ( Figure 2D) . The key cluster comprised of myeloid cells 3 4 2 like neutrophils-granulocytes, macrophage M1, BDCA1 + CD14 + and monocytes as the DACs. The DIME networks revealed immune system mediated mechanisms for the different 3 5 3 diseases. As observed in the Figure 2, Supplementary Figure 3 including those related to the neutrophil degranulation, degradation of ECM, interleukin and 3 5 6 TGF beta signaling pathways. These pathways and common mechanisms observed in the 3 5 7 DIME networks could serve as additional layers to understand the pathogenesis of these type 3 5 8 I interferon driven diseases 46 . We further explored such common mechanisms based on the 3 5 9
cell-gene relationships in the next section. Pleiotropy is when one gene affects two or more diseases 47 . Pleiotropy has been observed in several studies for many different diseases based on gene mutation to phenotype 3 6 4 associations 48 . Unlike most pleiotropy studies performed in the past that looks at only the 3 6 5 common DAGs between two diseases, we used a different approach. Since the DIME 3 6 6 networks from the previous analysis (for example, between SSc and pulmonary fibrosis) revealed several overlapping cell-gene connections, we extended this approach to look for diseases. Hence, we define pleiotropy in this study as the cell-gene connections that are found 3 7 0 in one or more diseases. Using this approach, we constructed the pleiotropy network as Within this pleiotropy network, we further looked at diseases that belong to different MeSH 3 8 4 terms and searched for common cell-gene mechanistic patterns between them. To do so, we 3 8 5 constructed the DIME-pleiotropy network of several pairs of phenotypically distinct diseases, the involvement of TGF beta signaling and ECM is well represented in the DIME-4 0 1 pleiotropy network and known to be implicated in literature [51] [52] [53] . Interestingly, we also signatures of the protective effect were not observed, we did find the presence of PTGS1 and NSAIDs taken by the RA patients that target the pro-inflammatory mediators 58 such as 4 2 3 PTGS1 and PTGS2 in both diseases, thus conferring protection.
2 4
These DIME-pleiotropy analyses highlighted the common cell-gene relationships between 4 2 5 the different diseases (Figure 3B-D) . Thus, making such pleiotropic relationships less 4 2 6 "ubiquitous" 59 but rather based on the similar cell-gene mechanism implicated between the 4 2 7 two diseases. We used this to further capture the plausible drug targets based on the immune 4 2 8 system mechanism as we identified with RA and colon cancer. Using our immunome data, the DisGeNet and the NMF, we constructed the DIME network 4 3 2 and the DIME-pleiotropy network (as described before and as depicted in Figure 4A , part 1 4 3 3
and 2). We extended this approach to construct drug-gene network to identify drug targets 4 3 4 based on the DIME network (Figure 4A, part 3) , which are referred to as the DIME-drug 4 3 5 network. We then used the pleiotropy method used before to then identify common drug 4 3 6 targets between the diseases (Figure 4A, part 4) based on the DIME-drug networks, which 4 3 7 forms the basis of the immunome mediated drug repurposing, (see methods). Figure 4B Crohn's disease 60 . In addition to the known drugs and drug targets, the DIME-drug network targets, such as lifitegrast that target the integrins, ITGB2 and ITGAL. This is particularly As we discovered common cell-gene mechanisms in the DIME-pleiotropy network in the 4 5 2 previous analysis (Figure 3) , we extended this approach to discover plausible drugs and drug 4 5 3 targets between the disease pair comparison to find new candidates for drug repurposing, we 4 5 4 refer to these analysis as the pleiotropy-drug network analysis (Figure 4A, part 4) . In 4 5 5 addition to the drug targets revealed from the DIME-drug network of Crohn's disease, the 4 5 6 pleiotropy drug network of Crohn's disease and psoriasis (Figure 4C) , comprised some 4 5 7 known drug targets such as IL6R for psoriasis and IL1B for Crohn's disease. The associated 4 5 8 drug of IL6R, tocilizumab is known to be used in the treatment for psoriasis 64 . Interestingly, were shown to have fewer cardiovascular events than placebo 67 .The pleiotropy drug network 4 7 0 of rheumatoid arthritis and colon carcinoma was found to be larger (Figure 4F) , due to the 4 7 1 larger overlap between the two diseases, see Figure 3D . The network shows possibilities of 4 7 2 using anti-inflammatory drugs for treatment or prevention of colon carcinoma as discussed 4 7 3 before. With drugs that target genes such as IL2RG, TYK2, PTGS1, PTGS2, etc. that are 4 7 4 widely used to treat anti-inflammatory or immune mediated diseases, these can be used as 4 7 5 preventive care drugs or for use along with chemotherapy 68 .
7 6
We also looked at the known drug targets that are present across the DIME networks of the 4 7 7 613 diseases analyzed by us. We found the top 5 drug targets to be BCL2 (Figure 4B, C and F), PTGS2 (Figure 4B, 4E-4F) , PIK3CD (Figure 4D, 4E) , CXCR4 (Figure 4B-4F ) and IL1B (Figure 4B, C, E, and F) that were implicated in the DIME networks of more than 200 of the pleiotropy-drug networks shown here (Figure 4B-4F Despite decades of experimental data on the understanding of the molecular mechanism of 4 9 3 diseases, we know little about the perturbations in the niche cell compartments that are 4 9 4 specific to the disease. To address this gap several efforts at the tissue 5-7 and immune cell 16,17 4 9 5 level have been performed to identify these disease specific compartments. However, 4 9 6 previous studies have concentrated at whole tissues, not distinguishing different immune cell important to understand which of the gene subsets contribute to a mechanism within the 5 0 0 different cell populations. A disease may have perturbations occurring at a single cell type or 5 0 1 at multiple cell types with completely different or similar genes being involved. To truly 5 0 2 understand a disease, it is essential to capture these cell-gene networks as holistically as To address the above-mentioned gap, we used the systems immunology approach of Gene Expression. Cell 175, 1701-1715.e16 (2018) . 18. SRA-Tools -NCBI. http://ncbi.github.io/sra-tools/. throughput sequencing data. Bioinformatics 31, 166-169 (2015) . 
